An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 18 Jul 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 18 Jul 2016 Status changed from not yet recruiting to recruiting.
- 13 Apr 2016 New trial record